• Skip to primary navigation
  • Skip to content
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

Press Releases

September 27, 2019

MedStar Heart & Vascular Institute Doses First Patient in Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy in Heart Failure Patients With Left Ventricular Assist Devices (LVADs)

Enrollment continues for first FDA-approved study involving multiple intravenous injections of mesenchymal stem cells for cardiovascular indications SAN DIEGO—Sept. 27, 2019—CardioCell, a biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces the treatment

Read More

Press Releases

December 11, 2018

CardioCell and MedStar Heart & Vascular Institute Initiate Phase IIa Clinical Trial to Assess Stem Cell Therapy Effects in Heart Failure Patients With Left Ventricular Assist Devices (LVADs)

News Dec 11, 2018 CardioCell and MedStar Heart & Vascular Institute Initiate Phase IIa Clinical Trial to Assess Stem Cell Therapy Effects in Heart Failure Patients With Left Ventricular Assist Devices (LVADs) FDA approves first study involving multiple intravenous injections of

Read More

News,  Press Releases

December 4, 2018

Innovative Stem Cell Therapeutic Strategy May be Transformative for Heart Failure Treatment

News Dec 4, 2018 Innovative Stem Cell Therapeutic Strategy May be Transformative for Heart Failure Treatment Washington, D.C.,  – The FDA has recently approved an investigational new drug clinical trial that will start shortly at MedStar Heart & Vascular Institute. The trial,

Read More

News,  Press Releases

April 25, 2018

CardioCell, in Collaboration With MedStar, Plans Clinical Trial That May Transform Therapy for Terminal Heart Failure Patients

News Apr 25, 2018 CardioCell, in Collaboration With MedStar, Plans Clinical Trial That May Transform Therapy for Terminal Heart Failure Patients SAN DIEGO — April 25, 2018 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for

Read More

News,  Press Releases

April 18, 2018

New Stem Cell Therapy May Transform Heart Failure Treatment

News Apr 18, 2018 New Stem Cell Therapy May Transform Heart Failure Treatment Washington, D.C., April 18, 2018 – Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with

Read More

News,  Press Releases

February 23, 2017

Positive Results From Pre-Clinical Studies Sponsored by CardioCell Post in the American Heart Association’s Journal “Circulation Research”

News Feb 23, 2017 Positive Results From Pre-Clinical Studies Sponsored by CardioCell Post in the American Heart Association’s Journal “Circulation Research” SAN DIEGO — Feb. 23, 2017 — Results from an acute myocardial infarction and an ischemic cardiomyopathy pre-clinical study

Read More

Press Releases

November 17, 2016

Positive Results From Study Sponsored by CardioCell Post in the American Heart Association’s Journal “Circulation Research”

News Nov 17, 2016 Positive Results From Study Sponsored by CardioCell Post in the American Heart Association’s Journal “Circulation Research” SAN DIEGO — Nov. 17, 2016 — Results from a study sponsored by CardioCell LLC, a global biotechnology company that uses allogeneic stem cells

Read More

News,  Press Releases

October 12, 2016

Independent Data Safety Monitoring Board (DSMB) Unanimously Recommends CardioCell’s Heart Failure Studies Continue

News Oct 12, 2016 Independent Data Safety Monitoring Board (DSMB) Unanimously Recommends CardioCell’s Heart Failure Studies Continue SAN DIEGO – Oct. 12, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces an

Read More

News,  Press Releases

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Page »

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2023 · Business Pro Theme on Genesis Framework · WordPress · Log in